Kuf-13046

Opaque identifiers present recurring challenges:

Concrete example: a maintenance team receives a work order referencing KUF-13046. If documentation is missing, technicians waste time locating the correct part, risking downtime and increased cost. KUF-13046

The trajectory of KUF-13046 mirrors that of many orphan compounds. Initially synthesized as a screening library candidate, it has gained "tool compound" status—a molecule used to validate biological targets. The critical questions moving forward include: Opaque identifiers present recurring challenges:

CAPS are a group of rare autoinflammatory diseases caused by gain-of-function mutations in the NLRP3 gene. Current treatments (like Canakinumab) are biologic antibodies requiring injection. KUF-13046 offers a proof-of-concept for an oral, small-molecule alternative. Early ex vivo studies using patient monocytes show that KUF-13046 suppresses spontaneous IL-1β secretion without cytotoxic effects. Concrete example: a maintenance team receives a work

Well-managed identifiers like KUF-13046 become enablers: